Data as of Dec 19
| -20.51 / -6.91%|
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It is also a leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. Roche employs over 85,000 people worldwide. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. The company was founded in 1896 and is headquartered in Basel, Switzerland.
|Severin Schwan||Chief Executive Officer & Director|
|Alan Hippe||Chief Financial & Information Technology Officer|
|Richard H. Scheller||Head-Genentech Research & Early Development|
|Hyam I. Levitsky||Head-Cancer Immunology Experimental Medicine|
|John C. Reed||Head-Roche Pharma Research & Early Development|